Patents by Inventor Leslie A. Khawli
Leslie A. Khawli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230331849Abstract: Applicant discloses herein an immunoconjugate, which enables systemic use of targeted CpG using a new class of antibodies which target the tumor microenvironment. Conjugation to checkpoint inhibitors such as anti-PD-L1, anti-CTLA-4, anti-LAGS anti-TIM-3, and anti-VISTA to make “biobetter” reagents.Type: ApplicationFiled: September 8, 2021Publication date: October 19, 2023Inventors: Alan Epstein, Peisheng Hu, Leslie Khawli
-
Patent number: 9522958Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.Type: GrantFiled: September 8, 2011Date of Patent: December 20, 2016Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 9486546Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: GrantFiled: July 31, 2015Date of Patent: November 8, 2016Assignee: GENENTECH, INC.Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
-
Patent number: 9393327Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: GrantFiled: December 18, 2013Date of Patent: July 19, 2016Assignee: GENENTECH, INC.Inventors: Charles Andrew Boswell, Leslie A Khawli, Jan Marik, Simon Williams
-
Publication number: 20160002121Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: ApplicationFiled: July 31, 2015Publication date: January 7, 2016Applicant: GENENTECH, INC.Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
-
Publication number: 20140170064Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: ApplicationFiled: December 18, 2013Publication date: June 19, 2014Applicant: Genentech, Inc.Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
-
Publication number: 20120076804Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.Type: ApplicationFiled: September 8, 2011Publication date: March 29, 2012Inventors: Alan L. Epstein, Leslie A. Khawli
-
Publication number: 20060135459Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.Type: ApplicationFiled: November 8, 2005Publication date: June 22, 2006Inventors: Alan Epstein, Leslie Khawli
-
Publication number: 20050214286Abstract: Described is a cancer therapeutic agent comprising a polymer to which is linked three or more anti-tumor cell antibodies. Soluble polymers of between 6-8 Kd in size are preferred. The antibodies of the polymer can bind to a tumor cell antigen of a tumor cell and induce apoptosis or cell death of the tumor cell. The polymer may be linked to different antibodies to the same tumor antigen or to different tumor antigens. Methods of treating an individual with cancer using the cancer therapeutic agent are also described.Type: ApplicationFiled: January 27, 2005Publication date: September 29, 2005Inventors: Alan Epstein, Leslie Khawli
-
Publication number: 20040156824Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: ApplicationFiled: February 27, 2004Publication date: August 12, 2004Inventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 6737064Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: GrantFiled: May 9, 2002Date of Patent: May 18, 2004Assignee: The University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Publication number: 20020164302Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: ApplicationFiled: May 9, 2002Publication date: November 7, 2002Inventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 6403096Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: GrantFiled: November 18, 1999Date of Patent: June 11, 2002Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 6008319Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.Type: GrantFiled: December 23, 1996Date of Patent: December 28, 1999Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 5990286Abstract: Modified antibodies which have been by chemical conjugation with agents reactive with free amino groups are disclosed. Among the chemical agents disclosed for use in connection with the invention are heterobifunctional reagents and biotin. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.Type: GrantFiled: January 10, 1997Date of Patent: November 23, 1999Assignee: Techniclone, Inc.Inventors: Leslie A. Khawli, Alan L. Epstein
-
Patent number: 5194594Abstract: Modified antibodies are disclosed which have been modified by chemical conjugation with a heterobifunctional reagent, such as SPDP. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in such diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.Type: GrantFiled: September 7, 1990Date of Patent: March 16, 1993Assignee: Techniclone, Inc.Inventors: Leslie A. Khawli, Alan L. Epstein
-
Patent number: 4994557Abstract: N-(m-radiohalophenyl) maleimide can be conjugated with a reduced antibody having a mercapto group to provide a radiolabelled half-antibody having immunological specific binding characteristics of whole antibody.Type: GrantFiled: January 29, 1988Date of Patent: February 19, 1991Assignee: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Leslie A. Khawli
-
Patent number: 4977288Abstract: m-Radiohalo-aniline is a stable intermediate for preparing biotin-m-radiohalo-anilide to be used as an imaging agent or therapeutic agent. The invention also contemplates m-aminophenyltrialkylstannane which can be radiohalogenated and linked to biotin.Type: GrantFiled: January 29, 1988Date of Patent: December 11, 1990Assignee: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Leslie A. Khawli